
Danaher Corporation
NYSE•DHR
CEO: Mr. Steven M. Rales
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1978-12-29
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Contact Information
2200 Pennsylvania Avenue, North West, Suite 800 West, Washington, DC, 20037-1701, United States
202-828-0850
Market Cap
$165.03B
P/E (TTM)
46.7
36.3
Dividend Yield
0.6%
52W High
$258.23
52W Low
$171.00
52W Range
Rank34Top 20.2%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$6.05B+4.40%
4-Quarter Trend
EPS
$1.28+13.27%
4-Quarter Trend
FCF
$1.37B+12.76%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Sales Growth Total sales reached $17.73B, up 2.5% for nine months; core sales grew 1.5% compared to prior year.
Q3 Margin Expansion Q3 operating margin improved 260 basis points to 19.1% driven by favorable Life Sciences impairment comparison.
Biotech Segment Strength Biotechnology segment sales grew 9.0% to $5.26B; operating profit margin remained strong at 25.2% for nine months.
Cash Generation Net cash provided by operating activities totaled $4.30B for the nine-month period ended September 26, 2025.
Risk Factors
Significant Impairment Charges Nine-month net earnings declined due to $548M impairment charges, primarily impacting Life Sciences segment results.
Life Sciences Core Decline Life Sciences core sales declined 2.5% for nine months amid market softness and reorganization impacts.
Trade Policy Uncertainty Ongoing uncertainty regarding US tariffs and regulatory changes poses material risk to revenue and profitability.
Intangible Asset Valuation Goodwill and intangible asset valuations rely on estimates; adverse changes could result in future impairment charges.
Outlook
New Debt Issuance Completed CHF 1.25B Swiss Bond offering in October 2025 for general corporate purposes and debt repayment.
Projected Tax Rate Expect effective tax rate around 17.0% for remainder of 2025 based on projected mix of earnings jurisdictions.
Strategic Technology Investment Significant investments planned in automation, AI, and technology to address rapid technological change in markets.
Liquidity Position Company maintains $1.5B liquidity to fund acquisitions, CapEx, and ongoing restructuring activities planned.
Peer Comparison
Revenue (TTM)
MCK$387.09B
PFE$62.79B
SNY$46.51B
Gross Margin (Latest Quarter)
GILD79.8%
PFE74.9%
SNY74.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TMO | $220.10B | 33.4 | 13.1% | 34.6% |
| ISRG | $206.41B | 75.0 | 16.1% | 0.0% |
| AMGN | $179.28B | 25.6 | 96.2% | 60.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.5%
Flat Growth
4Q Net Income CAGR
-5.8%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Jan 28, 2026
EPS:$2.14
|Revenue:$6.79B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 26, 2025|Filed: Oct 21, 2025|Revenue: $6.05B+4.4%|EPS: $1.28+13.3%MissForm 10-Q - Q2 2025
Period End: Jun 27, 2025|Filed: Jul 22, 2025|Revenue: $5.94B+3.4%|EPS: $0.77-37.4%MissForm 10-Q - Q1 2025
Period End: Mar 28, 2025|Filed: Apr 22, 2025|Revenue: $5.74B-0.9%|EPS: $1.33-9.5%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 20, 2025|Revenue: $23.88B-0.1%|EPS: $5.33-17.2%MissForm 10-Q - Q3 2024
Period End: Sep 27, 2024|Filed: Oct 22, 2024|Revenue: $5.80B+3.1%|EPS: $1.13-26.1%MissForm 10-Q - Q2 2024
Period End: Jun 28, 2024|Filed: Jul 23, 2024|Revenue: $5.74B-19.8%|EPS: $1.23-18.0%MissForm 10-Q - Q1 2024
Period End: Mar 29, 2024|Filed: Apr 23, 2024|Revenue: $5.80B-2.6%|EPS: $1.47-25.0%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 21, 2024|Revenue: $23.89B-10.3%|EPS: $6.44-34.3%Miss